Investigating the role of sphingosine-1-phosphate in pneumonia treatment
To Assess the Role of Sphingosine-1-phosphate in the Pathobiology of Pneumonia: Generate a New Strategy for Treatment of Severe Community-acquired Pneumonia
This study is testing if a substance called sphingosine-1-phosphate can help improve treatment for adults with pneumonia by seeing if it makes them feel better compared to a placebo.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Enrollment | 400 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Taipei Medical University WanFang Hospital Academic / other |
| Locations | 1 site (Taipei City) |
| Trial ID | NCT04007328 on ClinicalTrials.gov |
What this trial studies
This clinical trial explores the effects of sphingosine-1-phosphate (S1P) on patients with community-acquired pneumonia (CAP). It aims to determine whether S1P can serve as a biomarker for pneumonia and whether its modulation through the administration of methylprednisolone can improve patient outcomes. The study will involve patients aged 18 and older who exhibit symptoms of pneumonia and will compare the effects of S1P treatment against a placebo. The trial is designed to assess both the safety and efficacy of this approach in enhancing lung endothelial barrier integrity and reducing pneumonia severity.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with clinical symptoms suggestive of community-acquired pneumonia and a pneumonia severity index greater than 90.
Not a fit: Patients with severe immunosuppression, malignancies, or those currently using antibiotics or corticosteroids may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for pneumonia, potentially reducing mortality and healthcare burden.
How similar studies have performed: Previous studies have indicated the potential of S1P in lung injury contexts, suggesting that this approach may yield promising results, although it remains relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinical symptoms suggestive community-acquired pneumonia and pneumonia severe index (PSI) \> 90, Age 18 years or older and Written informed consent obtained Exclusion Criteria: * Presence of severe immunosuppression (HIV infection, use of immunosuppressants), malignancy, pregnancy or breastfeeding, patient with uncontrol diabetes, current use of antibiotics or corticosteroids, any likely infection other than CAP, or pneumonia that developed within 3 days after hospital discharge
Where this trial is running
Taipei City
- Wan Fang Hospital — Taipei City, Taiwan (Recruiting)
Study contacts
- Principal investigator: Ching-Wang Hsu, MD — Wan Fang Hospital
- Study coordinator: Shih-Chang Hsu, MD
- Email: 1980bradhsu@gmail.com
- Phone: 0982770936
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.